Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus-Positive Patients with Hematologic Disorders: A Report from the Center for International Blood and Marrow Transplant Research

Vikas Gupta; Marcie Tomblyn; Tanya L. Pedersen; Harry L. Atkins; Minoo Battiwalla; Ronald E. Gress; Marilyn S. Pollack; Jan Storek; Jill C. Thompson; Pierre Tiberghien; Jo Anne H Young; Patricia Ribaud; Mary M. Horowitz; Armand Keating

doi:10.1016/j.bbmt.2009.03.023

Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus-Positive Patients with Hematologic Disorders: A Report from the Center for International Blood and Marrow Transplant Research

Vikas Gupta, Marcie Tomblyn, Tanya L. Pedersen, Harry L. Atkins, Minoo Battiwalla, Ronald E. Gress, Marilyn S. Pollack, Jan Storek, Jill C. Thompson, Pierre Tiberghien, Jo Anne H Young, Patricia Ribaud, Mary M. Horowitz, Armand Keating

Medicine - Infectious Disease and International Medicine

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

The role of allogeneic hematopoietic cell transplantation (alloHCT) in human immunodeficiency virus (HIV)-positive patients is not known. Using the Center for International Blood and Marrow Transplant Research database, we retrospectively evaluated 23 HIV-positive patients undergoing matched sibling donor (n = 19) or unrelated donor (n = 4) alloHCT between 1987 and 2003. The median age at alloHCT was 32 years. Indications for alloHCT were diverse and included malignant (n = 21) and nonmalignant (n = 2) hematologic disorders. Nine patients (39%) underwent transplantation after 1996, the approximate year that highly active antiretroviral therapy became standard treatment. The median time to neutrophil engraftment was 16 days (range, 7 to 30 days), and the cumulative incidences of grade II-IV acute graft-versus-host disease (aGVHD) at 100 days, chronic GVHD (cGVHD), and survival at 2 years were 30% (95% confidence interval [CI] = 14% to 50%), 28% (95% CI = 12% to 48%), and 30% (95% CI = 14% to 50%), respectively. At a median follow-up of 59 months, 6 patients were alive. Survival appears to be better in the patients undergoing alloHCT after 1996; 4 of these 9 patients survived, compared with only 2 of 14 those undergoing transplantation before 1996. These data suggest that alloHCT is feasible for selected HIV-positive patients with malignant and nonmalignant disorders. Prospective studies are needed to evaluate the safety and efficacy of this modality in specific diseases in these patients.

Original language	English (US)
Pages (from-to)	864-871
Number of pages	8
Journal	Biology of Blood and Marrow Transplantation
Volume	15
Issue number	7
DOIs	https://doi.org/10.1016/j.bbmt.2009.03.023
State	Published - Jul 2009

Bibliographical note

Funding Information:
Financial disclosure: This project was supported by funding from the National Marrow Donor Program and the Health Resources and Services Administration (Contracts 240-97-0036 and 231-02-0007, to the National Marrow Donor Program). The views expressed in this article do not reflect the official policy or position of the Health Resources and Services Administration or the National Marrow Donor Program. The authors thank the data managers at the participating transplantation centers, whose diligence in obtaining and reporting the data made this study possible.

Keywords

Allogeneic
Bone marrow transplantation
Human immunodeficiency virus
Malignancy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.bbmt.2009.03.023

Find It

Find It at U of M Libraries

Cite this

Gupta, V., Tomblyn, M., Pedersen, T. L., Atkins, H. L., Battiwalla, M., Gress, R. E., Pollack, M. S., Storek, J., Thompson, J. C., Tiberghien, P., Young, J. A. H., Ribaud, P., Horowitz, M. M., & Keating, A. (2009). Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus-Positive Patients with Hematologic Disorders: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 15(7), 864-871. https://doi.org/10.1016/j.bbmt.2009.03.023

Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus-Positive Patients with Hematologic Disorders: A Report from the Center for International Blood and Marrow Transplant Research. / Gupta, Vikas; Tomblyn, Marcie; Pedersen, Tanya L. et al.
In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 7, 07.2009, p. 864-871.

Research output: Contribution to journal › Article › peer-review

Gupta, V, Tomblyn, M, Pedersen, TL, Atkins, HL, Battiwalla, M, Gress, RE, Pollack, MS, Storek, J, Thompson, JC, Tiberghien, P, Young, JAH, Ribaud, P, Horowitz, MM & Keating, A 2009, 'Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus-Positive Patients with Hematologic Disorders: A Report from the Center for International Blood and Marrow Transplant Research', Biology of Blood and Marrow Transplantation, vol. 15, no. 7, pp. 864-871. https://doi.org/10.1016/j.bbmt.2009.03.023

Gupta V, Tomblyn M, Pedersen TL, Atkins HL, Battiwalla M, Gress RE et al. Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus-Positive Patients with Hematologic Disorders: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation. 2009 Jul;15(7):864-871. doi: 10.1016/j.bbmt.2009.03.023

@article{8e72f7a9de0e4fc48ce01c0eca9f08a5,

title = "Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus-Positive Patients with Hematologic Disorders: A Report from the Center for International Blood and Marrow Transplant Research",

abstract = "The role of allogeneic hematopoietic cell transplantation (alloHCT) in human immunodeficiency virus (HIV)-positive patients is not known. Using the Center for International Blood and Marrow Transplant Research database, we retrospectively evaluated 23 HIV-positive patients undergoing matched sibling donor (n = 19) or unrelated donor (n = 4) alloHCT between 1987 and 2003. The median age at alloHCT was 32 years. Indications for alloHCT were diverse and included malignant (n = 21) and nonmalignant (n = 2) hematologic disorders. Nine patients (39%) underwent transplantation after 1996, the approximate year that highly active antiretroviral therapy became standard treatment. The median time to neutrophil engraftment was 16 days (range, 7 to 30 days), and the cumulative incidences of grade II-IV acute graft-versus-host disease (aGVHD) at 100 days, chronic GVHD (cGVHD), and survival at 2 years were 30% (95% confidence interval [CI] = 14% to 50%), 28% (95% CI = 12% to 48%), and 30% (95% CI = 14% to 50%), respectively. At a median follow-up of 59 months, 6 patients were alive. Survival appears to be better in the patients undergoing alloHCT after 1996; 4 of these 9 patients survived, compared with only 2 of 14 those undergoing transplantation before 1996. These data suggest that alloHCT is feasible for selected HIV-positive patients with malignant and nonmalignant disorders. Prospective studies are needed to evaluate the safety and efficacy of this modality in specific diseases in these patients.",

keywords = "Allogeneic, Bone marrow transplantation, Human immunodeficiency virus, Malignancy",

author = "Vikas Gupta and Marcie Tomblyn and Pedersen, {Tanya L.} and Atkins, {Harry L.} and Minoo Battiwalla and Gress, {Ronald E.} and Pollack, {Marilyn S.} and Jan Storek and Thompson, {Jill C.} and Pierre Tiberghien and Young, {Jo Anne H} and Patricia Ribaud and Horowitz, {Mary M.} and Armand Keating",

note = "Funding Information: Financial disclosure: This project was supported by funding from the National Marrow Donor Program and the Health Resources and Services Administration (Contracts 240-97-0036 and 231-02-0007, to the National Marrow Donor Program). The views expressed in this article do not reflect the official policy or position of the Health Resources and Services Administration or the National Marrow Donor Program. The authors thank the data managers at the participating transplantation centers, whose diligence in obtaining and reporting the data made this study possible. ",

year = "2009",

month = jul,

doi = "10.1016/j.bbmt.2009.03.023",

language = "English (US)",

volume = "15",

pages = "864--871",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus-Positive Patients with Hematologic Disorders

T2 - A Report from the Center for International Blood and Marrow Transplant Research

AU - Gupta, Vikas

AU - Tomblyn, Marcie

AU - Pedersen, Tanya L.

AU - Atkins, Harry L.

AU - Battiwalla, Minoo

AU - Gress, Ronald E.

AU - Pollack, Marilyn S.

AU - Storek, Jan

AU - Thompson, Jill C.

AU - Tiberghien, Pierre

AU - Young, Jo Anne H

AU - Ribaud, Patricia

AU - Horowitz, Mary M.

AU - Keating, Armand

N1 - Funding Information: Financial disclosure: This project was supported by funding from the National Marrow Donor Program and the Health Resources and Services Administration (Contracts 240-97-0036 and 231-02-0007, to the National Marrow Donor Program). The views expressed in this article do not reflect the official policy or position of the Health Resources and Services Administration or the National Marrow Donor Program. The authors thank the data managers at the participating transplantation centers, whose diligence in obtaining and reporting the data made this study possible.

PY - 2009/7

Y1 - 2009/7

N2 - The role of allogeneic hematopoietic cell transplantation (alloHCT) in human immunodeficiency virus (HIV)-positive patients is not known. Using the Center for International Blood and Marrow Transplant Research database, we retrospectively evaluated 23 HIV-positive patients undergoing matched sibling donor (n = 19) or unrelated donor (n = 4) alloHCT between 1987 and 2003. The median age at alloHCT was 32 years. Indications for alloHCT were diverse and included malignant (n = 21) and nonmalignant (n = 2) hematologic disorders. Nine patients (39%) underwent transplantation after 1996, the approximate year that highly active antiretroviral therapy became standard treatment. The median time to neutrophil engraftment was 16 days (range, 7 to 30 days), and the cumulative incidences of grade II-IV acute graft-versus-host disease (aGVHD) at 100 days, chronic GVHD (cGVHD), and survival at 2 years were 30% (95% confidence interval [CI] = 14% to 50%), 28% (95% CI = 12% to 48%), and 30% (95% CI = 14% to 50%), respectively. At a median follow-up of 59 months, 6 patients were alive. Survival appears to be better in the patients undergoing alloHCT after 1996; 4 of these 9 patients survived, compared with only 2 of 14 those undergoing transplantation before 1996. These data suggest that alloHCT is feasible for selected HIV-positive patients with malignant and nonmalignant disorders. Prospective studies are needed to evaluate the safety and efficacy of this modality in specific diseases in these patients.

AB - The role of allogeneic hematopoietic cell transplantation (alloHCT) in human immunodeficiency virus (HIV)-positive patients is not known. Using the Center for International Blood and Marrow Transplant Research database, we retrospectively evaluated 23 HIV-positive patients undergoing matched sibling donor (n = 19) or unrelated donor (n = 4) alloHCT between 1987 and 2003. The median age at alloHCT was 32 years. Indications for alloHCT were diverse and included malignant (n = 21) and nonmalignant (n = 2) hematologic disorders. Nine patients (39%) underwent transplantation after 1996, the approximate year that highly active antiretroviral therapy became standard treatment. The median time to neutrophil engraftment was 16 days (range, 7 to 30 days), and the cumulative incidences of grade II-IV acute graft-versus-host disease (aGVHD) at 100 days, chronic GVHD (cGVHD), and survival at 2 years were 30% (95% confidence interval [CI] = 14% to 50%), 28% (95% CI = 12% to 48%), and 30% (95% CI = 14% to 50%), respectively. At a median follow-up of 59 months, 6 patients were alive. Survival appears to be better in the patients undergoing alloHCT after 1996; 4 of these 9 patients survived, compared with only 2 of 14 those undergoing transplantation before 1996. These data suggest that alloHCT is feasible for selected HIV-positive patients with malignant and nonmalignant disorders. Prospective studies are needed to evaluate the safety and efficacy of this modality in specific diseases in these patients.

KW - Allogeneic

KW - Bone marrow transplantation

KW - Human immunodeficiency virus

KW - Malignancy

UR - http://www.scopus.com/inward/record.url?scp=66949130694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949130694&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.03.023

DO - 10.1016/j.bbmt.2009.03.023

M3 - Article

C2 - 19539219

AN - SCOPUS:66949130694

SN - 1083-8791

VL - 15

SP - 864

EP - 871

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 7

ER -

Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus-Positive Patients with Hematologic Disorders: A Report from the Center for International Blood and Marrow Transplant Research

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this